Valneva Seeks to Extend Use of Chikungunya Vaccine with Label Extension Submissions
Sep 19, 2024
Valneva Invest Information
Valneva Seeks to Extend IXCHIQ® Usage Through EMA and Health Canada Applications
Sep 18, 2024
Valneva's Innovative IXCHIQ® Becomes the First Chikungunya Vaccine Authorized in Europe
Jul 1, 2024
Valneva SE to Engage in Investor Conferences Highlighting June 2024 Agenda
Jun 4, 2024
Valneva Showcases Innovative Chikungunya Vaccine at World Vaccine Congress
Mar 21, 2024
Valneva SE Secures Extension of Interest-Only Period with Key Investors
Mar 19, 2024
Valneva SE's VALN Chikungunya Vaccine Receives FDA Approval, Company's Stock Rises
Nov 10, 2023